SGLT-2 inhibitors in type 1 diabetes mellitus: a comprehensive review of the literature.

CONCLUSION: This novel class of antidiabetics seems to be a very attractive treatment option in patients with T1DM, due to their multiple beneficial effects, but the increased risk of DKA should be taken into account.
PMID: 30084335 [PubMed - as supplied by publisher]

Source: Current Clinical Pharmacology - August 7, 2018 Category: Drugs & Pharmacology Authors: Patoulias D, Imprialos K, Stavropoulos K, Athyros V, Doumas M Tags: Curr Clin Pharmacol Source Type: research